ARRY / built-in buyers

Opkogulfbreeze

I am hoping for huge buyout so I have no exit strategy at this time

Best of luck!

Drangles

EXEL writeup from motley more on:

Exelixis claims a ridiculously high earnings multiple of 143. However, that ratio is based on the biotech's earnings over the last 12 months. Exelixis stock trades at nearly 43 times expected earnings -- still giving the stock a steep valuation.

Investors have great expectations for Exelixis' cancer drug Cabometyx. The drug has already captured 35% of the market as a second-line treatment for renal cell carcinoma (RCC), the most common type of kidney cancer. Exelixis awaits approval for an even bigger market as a first-line treatment for the disease.

However, Exelixis will have competition. Bristol-Myers Squibb (NYSE:BMY) recently announced results from its late-stage study of Opdivo and Yervoy as a first-line treatment for RCC. Even Exelixis CEO Michael Morrissey called those results "a clear win" for Bristol-Myers Squibb.

Exelixis faces two primary hurdles to avoid a stock meltdown: win approval for Cabometyx in the first-line RCC indication, and succeed commercially. There is certainly some risk that the biotech won't deliver. However, I think Exelixis has pretty good odds for achieving both goals. I also expect Exelixis could find itself an acquisition target down the road.
==============================

C L

XBI: 87 of 102 stocks are up.

IBB: 139k of 160 stocks are up.

No news from ARRY.